Loading...
Market
Public reaction to U.S. Senate HELP Committee's actions by December 31, 2024
5
Resolution / Starting Odds
Positive reaction • 33%
Neutral reaction • 33%
Negative reaction • 33%
Public opinion polls, media coverage, or official statements
Story
U.S. Senate Panel to Vote on June 18 on Subpoena for Novo Nordisk Over Ozempic, Wegovy Prices
Jun 11, 2024, 03:00 PM
The U.S. Senate Health, Education, Labor, and Pensions (HELP) Committee, chaired by Senator Bernie Sanders, announced it will vote on June 18 to decide whether to subpoena Doug Langa, President of Novo Nordisk Inc. This action is prompted by the significant price disparity for weight loss drugs Ozempic and Wegovy between the U.S. and other countries. Americans are charged $969 for Ozempic, while Germans pay only $59. The committee seeks an explanation for why these drugs cost up to 10 to 15 times more in the U.S. compared to other nations. Novo Nordisk has not yet provided a satisfactory response to these inquiries. The vote will take place later this month.
View original story
Similar markets
Positive reaction • 33%
Negative reaction • 33%
Mixed reaction • 33%
Widespread support from both parties • 33%
Support from Republicans, opposition from Democrats • 33%
Opposition from both parties • 33%
Increased public support • 25%
Decreased public support • 25%
No significant change • 25%
Mixed reactions • 25%
Widespread criticism • 33%
Mixed reactions • 33%
Minimal attention • 33%
Generally Positive • 33%
Neutral • 33%
Generally Negative • 34%
Significantly negative • 25%
Somewhat negative • 25%
Neutral or no change • 25%
Positive • 25%
Majority Support Increased Aid • 33%
Majority Support Current Levels • 33%
Majority Oppose Increased Aid • 33%
Mostly positive • 25%
Mixed reactions • 25%
Mostly negative • 25%
Indifferent/no strong opinion • 25%
Strongly Support • 25%
Somewhat Support • 25%
Somewhat Oppose • 25%
Strongly Oppose • 25%
Broadly favorable • 25%
Broadly unfavorable • 25%
Mixed reactions • 25%
Indifference • 25%